Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory DLBCL or Grade IIIB FL
NCT05633615Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2023
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mosunetuzumab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and primary mediastinal large B-cell lymphoma (PMBCL) (4 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival up to 2 years. Started Jun 2023; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT05633615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633615.